Pivotal Phase 3 trial of GTX-102 expected to launch by year’s end
Authorities in both the U.S. and Europe have provided positive feedback to Ultragenyx Pharmaceutical regarding plans for a Phase 3 clinical trial testing its gene therapy candidate GTX-102 in people with Angelman syndrome. Now, having completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA),…